{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:33Z","timestamp":1786987053498,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","award":["NCT05160584"],"award-info":[{"award-number":["NCT05160584"]}],"id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","award":["NCT04035226"],"award-info":[{"award-number":["NCT04035226"]}],"id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clml.2025.03.014","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T03:57:20Z","timestamp":1743307040000},"page":"646-655.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies"],"prefix":"10.1016","volume":"25","author":[{"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Esther Gonzalez","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5494-9009","authenticated-orcid":false,"given":"Marta Sonia Gonzalez","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Lindsey-Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suriya","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Di","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Strulev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Im\u00e8ne","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silva","family":"Koskinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Acciarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefien","family":"Buyze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.03.014_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-022-05058-5","article-title":"The emerging therapeutic landscape of relapsed\/refractory multiple myeloma","volume":"102","author":"Tanenbaum","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.03.014_bib0002","series-title":"Paper presented at: 20th International Myeloma Society (IMS) Annual Meeting","first-page":"27","article-title":"Standard of care outcomes in the last 3 years in patients with triple-class exposed relapsed\/refractory multiple myeloma: the first pooled analysis of LocoMMotion and MoMMent trials","author":"Weisel","year":"2023"},{"key":"10.1016\/j.clml.2025.03.014_bib0003","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.03.014_sbref0004","series-title":"Prescribing Information","year":"2023"},{"key":"10.1016\/j.clml.2025.03.014_bib0005","series-title":"Summary of Product Characteristics","year":"2023"},{"key":"10.1016\/j.clml.2025.03.014_sbref0006","series-title":"Prescribing Information","year":"2021"},{"key":"10.1016\/j.clml.2025.03.014_bib0007","series-title":"Summary of Product Characteristics","year":"2021"},{"key":"10.1016\/j.clml.2025.03.014_bib0008","series-title":"Summary of Product Characteristics","year":"2023"},{"key":"10.1016\/j.clml.2025.03.014_bib0009","series-title":"Prescribing Information","year":"2023"},{"key":"10.1016\/j.clml.2025.03.014_bib0010","series-title":"Prescribing Information","year":"2023"},{"key":"10.1016\/j.clml.2025.03.014_bib0011","series-title":"Summary of Product Characteristics","year":"2022"},{"key":"10.1016\/j.clml.2025.03.014_bib0012","series-title":"Prescribing Information","year":"2023"},{"key":"10.1016\/j.clml.2025.03.014_sbref0013","series-title":"Summary of Product Characteristics","year":"2023"},{"key":"10.1016\/j.clml.2025.03.014_bib0014","unstructured":"Mateos M-V, Weisel K, Gonzalez Garcia ME, et al. Real-life outcomes in triple-class exposed relapsed\/refractory multiple myeloma treated with carfilzomib- and\/or pomalidomide-based regimens in the LocoMMotion and MoMMent studies. Paper presented at: 21st International Myeloma Society (IMS) Annual Meeting; September 27\u201330, 2023; Rio de Janeiro, Brazil."},{"key":"10.1016\/j.clml.2025.03.014_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.03.014_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.03.014_bib0017","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations","volume":"194","author":"Rosi\u00f1ol","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.03.014_bib0018","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.03.014_bib0019","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/ejh.13426","article-title":"Impact of performance status on overall survival in patients with relapsed and\/or refractory multiple myeloma: real-life outcomes of daratumumab treatment","volume":"105","author":"Afram","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2025.03.014_bib0020","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.03.014_bib0021","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and Dexamethasone in heavily pretreated relapsed and refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.03.014_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12041035","article-title":"Carfilzomib based treatment strategies in the management of relapsed\/refractory multiple myeloma with extramedullary disease","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2025.03.014_bib0023","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-140243","article-title":"Chimeric antigen receptor T cell therapy in the relapsed or refractory multiple myeloma with extrameullary disease\u2014a single institution observation in china","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.03.014_bib0024","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel","volume":"17","author":"Zanwar","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2025.03.014_bib0025","series-title":"Paper presented at: 21st International Myeloma Society (IMS) Annual Meeting","first-page":"25","article-title":"Talquetamab + teclistamab in patients with relapsed\/refractory multiple myeloma: updated phase 1b results from RedirecTT-1 with >1 year of follow-up","author":"Cohen","year":"2024"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:19:10Z","timestamp":1762600750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2152265025001065"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}